Monday, July 15, 2013

Six Strategies for Medical Device Startups


Six Strategies for Cash-Strapped Medical Device Startups**

Thanks to innovations in medical technology, people today are living longer, healthier, more productive and independent lives. Advances such as stents, artificial hips, insulin pumps, deep brain stimulators, and implantable defibrillators have improved the overall quality of care and lowered healthcare costs. Venture capital firms and angel investors are still funding early-stage companies that solve a real market need, have a solid leadership team in place, and have a capital efficient business model. The article, below, provides an overview on strategies that emerging medical device companies need to deploy, including the right ways to utilize PR/marketing initiatives prior to commercialization, to generate growth and become self-sustaining or profitable in the shortest amount of time possible.
**SOURCE: MDDI [Medical Device + Diagnostic Industry], originally published: May 10, 2012, Author: Charlie Chi, PhD

The U.S. medical device industry is a true American success story. More than half of the healthcare products purchased around the world come from medical technology companies based in this country. Yet this crown jewel of industry is now in serious jeopardy. According to a December 2011 survey conducted by the National Venture Capital Association (NVCA), 58% of venture capitalists expect an investment decrease in the biopharmaceutical and medical device sectors in 2012. This downward trend has been continuing since 2007, according to PricewaterhouseCoopers / NVCA, with fewer first-time companies receiving funding.
Decreased investment in early-stage medical device companies could be attributed to several factors. First, according to NVCA, it is getting more difficult for venture capitalists to raise funds for investment. This is likely a result of current economic challenges. Second, regulatory and reimbursement uncertainties in the United States are causing venture capital firms to rethink investing in U.S. medical technologies. Instead, many are shifting their investment to later stage medical device companies, to overseas ventures, or to Web-based or digital media companies. Third, the cost and time to exit have increased while the size of the exit remains roughly the same, making investment returns significantly less attractive than in the past. In addition, current tax policy and potential cuts in reimbursement by payors also threaten to stifle the industry’s next wave of innovation.
As a result of these factors, the United States could lose its leading position in the global medical technology market. Worse yet, patients, healthcare providers and the overall healthcare system may suffer a range of unintended consequences, including lower quality of care and higher costs. Furthermore, securing early-stage financing would likely become even more challenging for emerging U.S. medical device companies.
Fortunately, venture capital firms and angel investors are still funding early-stage companies that solve a real market need, have a solid leadership team in place, and have a capital efficient business model. In this new model, emerging medical device companies need to use cash efficiently to generate growth and become self-sustaining or profitable in the shortest amount of time possible. What follows is a description of a capital-efficient business model and why it is in the best interest of early stage companies and their stakeholders to accomplish as much as they can with as little cash as possible:
1. The Right Team
With a capital-efficient business model, companies have limited resources and typically only have one shot to get it right before running out of cash. Getting the right team in place is one of the main pillars of a capital-efficient business model because doing so can save both time and money. Thus, start-ups should consider partnering with professionals who have the right knowledge and experience, such as successful medical device business co-founders or entrepreneurs, champions or mentors. In addition, finding someone who has commercial experience in a similar industry or has commercialized a comparable technology or device in the past can be extremely helpful. First of all, such individuals can greatly help in determining the minimum amount of capital needed to commercialize the product, determine the regulatory and business strategy, including a capital-efficient business model, and develop an execution and/or exit plan. Secondly, these individuals can also help recruit and hire other key team members, such as management, finance, regulatory, or technical personnel, when necessary. Finally, such persons can also make introductions to investors, such as angels or venture capitalists, when appropriate.
2. Time is of the Essence
Emerging medical device companies should focus on getting their product into the hands of customers earlier rather than later. It will be important to keep in mind that it is not necessary to build the perfect product or develop the perfect process at the very beginning. It is more critical to find a balance between speed to market and developing the right product for the first commercial launch. Once the product is commercialized, emerging companies have ample opportunities to refine the product or process from customer feedback.
The goal of any emerging medical device company should be to out-innovate larger competitors, as well as get one’s product to market before other start-up companies can do so. To succeed, emerging companies should identify the key product requirements and essential features that would result in a shorter development time and, in some cases, faster regulatory clearance. Too many times, start-up companies become bogged down by focusing too much on process and too little on product development. Manufacturing and process efficiencies, such as cost reduction, can be outsourced or refined after the product is commercialized.
In many cases, being the first to market allows medical device start-ups to sell their products at higher prices, set product requirements, establish regulatory and quality standards ahead of the competition, and obtain valuable customer feedback to further improve and refine their products. Achieving this does not mean one needs to skimp on quality or patient safety, as some might suspect. Emerging device companies must follow proper regulatory and quality protocols, obtain the necessary permits or licenses, and perform the necessary testing to ensure that the product is made with the highest quality and reliability possible. In essence, the product must meet and comply with appropriate standards to ensure patient safety.
3. Choosing a Sound Regulatory Strategy
When following a capital-efficient business model, companies may choose to seek regulatory approval and launch their products overseas before doing so in the United States. From a timeline perspective, there is generally a one- to three-year delay in launching new medical devices into general clinical practice in the United States compared to in the European Union, for example. This is partly because the regulatory process in Europe is less bureaucratic, more efficient, and more predictable than in the United States. Another reason is that FDA requires evidence of both safety and efficacy of a device, whereas a European CE Mark only requires proof of safety and that the device performs in a manner consistent with the manufacturer’s intended use. Also, it is becoming ever more difficult and arduous to conduct clinical trials in the United States as a result of FDA’s clinical data requirements (reference device regulation guidance documents available at www.fda.gov). Thus, the timeline for obtaining a CE Mark is typically much shorter than the timeline for gaining FDA approval.
In some scenarios, emerging medical device companies can start the approval process in the United States and overseas in tandem. This is the ideal strategy in terms of reducing regulatory risk due to costly delays in the launch of a device, but requires more financial resources. It is important to note here that most venture capitalists today require medical device companies to develop parallel regulatory strategies before funding. Thus, start-up companies need to determine the various regulatory options and develop capital and time efficient business strategies that include both the United States and other countries. To determine the right regulatory strategy, companies should seek advice from regulatory experts as early as possible.
4. Growing Carefully Through Strategic Marketing
Another important consideration for emerging medical device companies is to grow very carefully. This does not mean slowly, but wisely in a smaller market first…it will be more important for them to focus on local or regional markets initially to validate their products. The local or regional markets can be thought of as the launching pads for national and international sales. Selling locally or regionally first can help companies hone their sales pitches to healthcare providers, validate their products clinically, and prove to customers, distribution partners or potential acquirers that their products can be game changers in terms of efficiency, cost savings or better clinical outcomes. Launching products nationally too quickly without proper market and product validation can be disastrous for emerging companies if not done properly.
There are several marketing tactics to sell and promote new medical devices locally and regionally with limited funding. Examples include positive media coverage (also known as “free media”) obtained through public relations outreach, word-of-mouth “advertising,” and customer testimonials campaigns. We will discuss how each of these approaches can be used to promote and sell your products with limited cash and resources.
Media coverage can greatly help spread the word about new products or companies. When a new medical device is used successfully on a patient in a local or regional hospital, local or regional media are often very interested in doing a human-interest story. In some cases, local or regional media coverage is picked up by national news outlets, especially if the patient or technology makes for an exciting or important story. Media coverage can boost brand awareness and sales tremendously. Unlike advertisements, articles and stories in the press are viewed by the public as third-party endorsements.
Selling locally or regionally can also generate word-of-mouth “advertising” without a large marketing budget. Inspiring patients, healthcare professionals and customers to talk about a new product creates a “buzz” in the community. No form of marketing is more powerful than patients telling their friends, families and co-workers about their great new medical device and their much-improved health. As a side note, allowing certain influential customers (physicians or hospitals) exclusivity in a local or regional market for a period of time can create competition, which will drive demand in the long term.
Finally, getting the right customers talking can help validate and promote a new medical product or technology in a local or regional market. In every community, there are the early adopters, who usually are highly influential, and the followers, who wait to hear what others have to say, then follow. If emerging companies can market and sell their products to these early adopters and get them talking, they can usually influence the followers. One of the best and most cost-effective ways to maximize customer testimonials is to ask influential customers to give their testimonials in various local or regional markets in the form of media interviews, presentations to physicians and/or patients, live surgeries or product demonstrations, or physician referrals. Testimonials on the start-up’s Web site, in Blog posts or on social media platforms can also be effective.
5. Outsourcing Non-Critical Business Functions
With a capital-efficient business model, it is necessary to leverage external resources where appropriate. Emerging medical device companies should focus on their core technology, such as research, design and innovation, and outsource non-critical business functions, such as payroll, accounting, HR, and IT. Trying to own all of the business functions in-house and build one’s own team and infrastructure from scratch could be time-consuming and costly. There are plenty of consulting and service companies that specialize in non-core business functions that can do the job more efficiently and less costly than start-up companies.
Generally speaking, companies can also leverage offshore or on the ground consultants and design service companies to outsource their product development. Start-ups that choose this path must be careful to ensure that the product development is done under certain budget constraints and on a strict timeframe. In some instances, hiring or retaining an offshore project manager can avoid costly delays or mistakes, especially in countries where language, culture and communication could be potential obstacles. Emerging companies seeking this path should consult with outsourcing professionals that can help them avoid costly time delays.
6. Compensation for Sales Team
For start-ups operating with limited cash and resources, hiring and supporting a permanent sales team is extremely expensive; paying commissions is much more cost-effective. The ideal situation for a start-up is to have all of its sales team paid purely on commission with no base salary and benefits, such as paid vacations and health insurance. In some industries where pure commissions are not the norm, offering a minimum base salary may be necessary to attract stronger sales representatives. In addition, equity in terms of stock options might offer additional incentives for sales representatives to join a start-up’s sales team. For emerging medical device companies that need to build a productive sales team in a short timeframe, independent sales consultants paid purely on commission is the ideal way to go.
Conclusion
Considering today’s uncertain regulatory climate and challenging economic environment, emerging medical device companies have to accomplish more with less. In this article, I have discussed why a capital-efficient business model makes sense for early-stage companies seeking venture capital funding. It may also apply to some later stage companies that would like to operate more cost efficiently. Following the traditional business model for raising several rounds of financing before a start-up company becomes profitable or is acquired is no longer attractive to venture investors. This is due to lower valuation compared to other industries (such as Web-based or social networking companies). On the brighter side, the opportunities for medical device technologies have never been greater for the United States and abroad. As mergers and acquisitions continue to pcik up, venture capitalists are shifting their focus and looking for new opportunities to invest in early-stage companies with innovative medical technologies. Emerging medical device companies that can think outside the box by accomplishing more with less cash will ultimately succeed.
ABOUT THE AUTHOR: Charlie Chi, PhD is an electrical and computer science engineer with more than 15 years of management, operations, product development, manufacturing, and consulting experience in the medical device and high technology industries. Currently, Dr. Chi is a consultant to medical device companies throughout California and in other states. Dr. Chi is former president, CEO, and co-founder of OtisMed (now part of Stryker Orthopaedics), a medical device company co-founded by Dr. Chi to address unmet clinical problems in orthopedics. Dr. Chi can be contacted at (415) 234-7968 or charlie@drcharliechi.com.


Thursday, June 27, 2013

Oncology Clinical Trial News Update Peregrine Pharmaceuticals (NASDAQ: PPHM)


Peregrine Pharmaceuticals (NASDAQ: PPHM) Provides Update on Bavituximab Clinical Program

Company Strengthens Cash Position as It Prepares to Initiate Phase III Trial in Second-Line NSCLC by Year-End While Partnering Discussions Continue; Recent Data Supporting Novel Immunotherapy Mechanism of Action Prompts Review of Ongoing Trials Including Early Review of Phase II Front-Line NSCLC Trial; Company Accelerating Collection of Immune Correlative Data From Ongoing Trials While New Immunotherapy Combination Studies Are Being Planned

Full Press Release Follows.

SOURCE: Peregrine Pharmaceuticals, June 27, 2013 08:30 ET

TUSTIN, CA--(Marketwired - Jun 27, 2013) - Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today provided an update on its bavituximab oncology program including financing activities focused on advancing its lead program into a pivotal Phase III trial and adapting its clinical development plan in accordance with the recent increased understanding of the immune-stimulatory properties of bavituximab. In May, the company reached an agreement with the Food and Drug Administration (FDA) on a Phase III trial design in second-line non-small cell lung cancer (NSCLC) with bavituximab and docetaxel, presented data from its trial supporting this study in early June and is now in the process of initiating the pivotal Phase III trial by year-end. In line with the planning for the Phase III trial and continued development in other indications, the company received over $24 million in net proceeds since its quarter-end January 31, 2013 through an At Market Issuance Sales Agreement and had over $42 million in cash as of June 24, 2013.

Data recently presented at the annual meeting of the American Association for Cancer Research (AACR) yielded definitive insight into bavituximab's immunotherapy mechanism of action. These data prompted Peregrine to undertake a review of its entire ongoing bavituximab clinical program in order to better direct its clinical development and further explore its therapeutic potential. Several of the ongoing investigator-sponsored trials (IST) include immune correlative testing which could corroborate bavituximab's immunotherapy mechanism of action in the clinic. The company is also actively working with its clinical collaborators on how best to design future trials evaluating the potential of combining bavituximab with other immunotherapy agents in addition to the chemotherapy combinations that are currently underway.

To further focus the strategic direction for potential upcoming trials, Peregrine just completed an analysis of overall survival (OS) data from its Phase II clinical trial comparing bavituximab plus carboplatin and paclitaxel versus carboplatin and paclitaxel alone in front-line patients with Stage IIIb and Stage IV NSCLC. This analysis, with less than 60% of survival events, indicated that while the bavituximab containing treatment arm currently demonstrates a median overall survival of over 14 months, there was not a meaningful enough difference in survival between the two arms of the trial that would support the advancement of this combination. Full results from the trial will be presented at a future scientific meeting or through publication.

"These recent data supporting an immunotherapy mechanism of action for bavituximab opens many new development opportunities including new combinations not previously planned and has created a lot of excitement around the potential of bavituximab in combination with other immunotherapeutic agents," stated Joseph Shan, vice president of clinical and regulatory affairs at Peregrine. "While exploring these opportunities, our primary focus remains on the initiation of the Phase III trial in second-line NSCLC by year-end based on promising survival data and we are on track to achieve that goal."

The Phase III clinical trial design will be a randomized, double-blind, placebo-controlled trial evaluating bavituximab plus docetaxel versus docetaxel alone. The trial will enroll approximately 600 patients with metastatic, non-squamous NSCLC who have progressed after standard front-line therapy. The primary endpoint of the trial will be OS.

"The recent agreement with the FDA on the Phase III trial design, along with the successful fundraising efforts have positioned us well for advancing the program into Phase III development, and have strengthened our position to develop the compound including ongoing partnering discussions," stated Steven W. King, president and chief executive officer of Peregrine. "We expect these developments will lead to important milestones during the second-half of the year as we advance the bavituximab program and gain further insight into its potential."

In March, data from a series of preclinical studies presented at the Annual Meeting of the American Association for Cancer Research (AACR) demonstrated that phosphatidylserine (PS)-targeting antibodies, such as bavituximab, mediate immuno-stimulatory changes in tumors by acting on upstream immune checkpoints and transforming those immune cells that are inhibiting immune recognition (MDSC's) into tumor-fighting (M1) macrophages and activated dendritic cells that lead to the formation of tumor fighting T-cells. Leveraging these findings, Peregrine has initiated studies to further validate this mechanism and evaluate how to best assess this in the four ongoing ISTs of breast, front-line NSCLC, rectal and liver cancers.

"By strengthening our cash position we have given ourselves the needed flexibility to prepare for the upcoming Phase III trial, explore the potential of bavituximab's immune mechanism and to strengthen our position in partnering discussions," stated Paul Lytle, chief financial officer at Peregrine. "Based on our current financial projections, we expect our cash resources to be sufficient to fund our operations for at the least the next twelve months as we continue to explore all of our opportunities."

As of June 24, 2013, the company has $42.0 million in cash and cash equivalents compared to $26.3 million at its quarter-end January 31, 2013 and $35.2 million at its year-end April 30, 2013. Prior to the recent front-line NSCLC data analysis, the company received $24.8 million in net proceeds since January 31, 2013 through the issuance of equity under its At Market Issuance Sales Agreement in exchange for 16.8 million shares of common stock sold at market prices. Peregrine intends to use these proceeds to prepare for the initiation of the pivotal Phase III clinical trial of bavituximab in second-line non-small cell lung cancer and for other general corporate purposes. Peregrine will report financial results for the fourth quarter of the fiscal year 2013 on July 11, 2013 after market.

About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the company may not be able to initiate the Phase III trial within its anticipated timeline, the risk that the results from the Phase III trial may not support a future BLA submission, the risk that the company may not have or raise adequate financial resources to complete the Phase III trial and the risk that the company may not find a suitable partner for the Phase III trial or the PS program. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in our reports filed with the Securities and Exchange Commission including, but not limited to, our annual report on Form 10-K for the fiscal year ended April 30, 2012 and our quarterly report on Form 10-Q for the quarter ended January 31, 2013. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.


Contact Information

Contact:  

Christopher Keenan or Jay Carlson

Peregrine Pharmaceuticals, Inc.

(800) 987-8256

info@peregrineinc.com

Thursday, June 20, 2013

Google's Insights, Recruitment & Hiring


In the ongoing battle for talent, no company musters the same resources quite like Google. Google recently shared its insights on recruitment and hiring. One of the key insights: the importance of effectively evaluating candidates for desired behavioral traits, such as solving problems where “there isn’t an obvious answer.” Forget about asking the candidate to calculate how many golf balls will fit into a 747 airplane. “The interesting thing about the behavioral interview is that when you ask somebody to speak to their own experience, and you drill into that, you get two kinds of information. One is you get to see how they actually interacted in a real-world situation, and the valuable ‘meta’ information you get about the candidate is a sense of what they consider to be difficult.”
Full article appears below.

SOURCE: On GPAs and Brainteasers: New Insights From Google On Recruiting and Hiring (Date: June 20 2013)
Author: Adam Bryant

We found that brainteasers are a complete waste of time. How many golf balls can you fit into an airplane? How many gas stations in Manhattan? A complete waste of time. They don’t predict anything. They serve primarily to make the interviewer feel smart.”
That was just one of the many fascinating revelations that Laszlo Bock, Google’s senior vice president for people operations, shared with me in an interview that was part of the New York Times’ special section on Big Data published Thursday.

Bock’s insights are particularly valuable because Google focuses its data-centric approach internally, not just on the outside world. It collects and analyzes a tremendous amount of information from employees (people generally participate anonymously or confidentially), and often tackles big questions such as, “What are the qualities of an effective manager?” That was question at the core of its Project Oxygen, which I wrote about for the Times in 2011.
I asked Bock in our recent conversation about other revelations about leadership and management that had emerged from its research.
The full interview is definitely worth your time, but here are some of the highlights:
The ability to hire well is random. “Years ago, we did a study to determine whether anyone at Google is particularly good at hiring,” Bock said. “We looked at tens of thousands of interviews, and everyone who had done the interviews and what they scored the candidate, and how that person ultimately performed in their job. We found zero relationship. It’s a complete random mess, except for one guy who was highly predictive because he only interviewed people for a very specialized area, where he happened to be the world’s leading expert.”
Forget brain-teasers. Focus on behavioral questions in interviews, rather than hypotheticals. Bock said it’s better to use questions like, “Give me an example of a time when you solved an analytically difficult problem.” He added: “The interesting thing about the behavioral interview is that when you ask somebody to speak to their own experience, and you drill into that, you get two kinds of information. One is you get to see how they actually interacted in a real-world situation, and the valuable ‘meta’ information you get about the candidate is a sense of what they consider to be difficult.”
Consistency matters for leaders. “It’s important that people know you are consistent and fair in how you think about making decisions and that there’s an element of predictability. If a leader is consistent, people on their teams experience tremendous freedom, because then they know that within certain parameters, they can do whatever they want. If your manager is all over the place, you’re never going to know what you can do, and you’re going to experience it as very restrictive.
GPAs don’t predict anything about who is going to be a successful employee. “One of the things we’ve seen from all our data crunching is that G.P.A.’s are worthless as a criteria for hiring, and test scores are worthless — no correlation at all except for brand-new college grads, where there’s a slight correlation,” Bock said. “Google famously used to ask everyone for a transcript and G.P.A.’s and test scores, but we don’t anymore, unless you’re just a few years out of school. We found that they don’t predict anything. What’s interesting is the proportion of people without any college education at Google has increased over time as well. So we have teams where you have 14 percent of the team made up of people who’ve never gone to college.”
That was a pretty remarkable insight, and I asked Bock to elaborate.
“After two or three years, your ability to perform at Google is completely unrelated to how you performed when you were in school, because the skills you required in college are very different,” he said. “You’re also fundamentally a different person. You learn and grow, you think about things differently. Another reason is that I think academic environments are artificial environments. People who succeed there are sort of finely trained, they’re conditioned to succeed in that environment. One of my own frustrations when I was in college and grad school is that you knew the professor was looking for a specific answer. You could figure that out, but it’s much more interesting to solve problems where there isn’t an obvious answer. You want people who like figuring out stuff where there is no obvious answer.”
Please share your thoughts on these insights below, and as I’ll be writing frequently on LinkedIn, please hit my FOLLOW button to see future posts.
ABOUT THE AUTHOR:
Adam Bryant has interviewed more than 200 leaders for his "Corner Office" feature that runs every Friday and Sunday in The New York Times. He is the author of the New York Times bestseller, "The Corner Office: Indispensable and Unexpected Lessons from CEOs on How to Lead and Succeed." His second book,“Quick and Nimble: Creating a Corporate Culture of Innovation," will be published in January.